Cholesstrinol lawsuit
This article was originally published in The Tan Sheet
Executive Summary
SourceOne Global Partners files a lawsuit against KGK Synergize following a dispute about intellectual property originally licensed to SourceOne for KGK's Sytrinol heart health supplement. The complaint filed Dec. 29 in U.S. District Court for the Northern District of Illinois, Eastern Division, says SourceOne's Cholesstrinol supplements do not infringe KGK's patent, and alleges that KGK made false and derogatory statements about SourceOne and its products. In a Jan. 7 statement, London, Ontario-based KGK says the lawsuit is SourceOne's "effort to sidetrack our termination of their license and our letter pointedly telling them to cease and desist their infringement." Chicago-based SourceOne launched the Cholesstrinol line in February 2008 (1"The Tan Sheet" March 17, 2008, p. 14)
You may also be interested in...
New Products In Brief
Natrol new at Expo West: Natrol announces March 5 it would launch new products at Expo West in Anaheim, Calif., including BioSil, a "bio-available, collagen generating supplement" shown to reduce fine lines and wrinkles in skin, thicken and strengthen hair and strengthen nails, as well as promote bone mineral density and healthy joints. A 30-count 5 mg bottle carries an SRP of $18.95. Another product Natrol planned to unveil at the March 13-15 event is Natrol 5-HTP Time-Release 200 mg, a "drug-free, plant-derived source of an amino acid that naturally increases the body's level of serotonin to help promote relaxation, calm and greater appetite control, as well as helping to support a more positive mood." A 30-count bottle carries an SRP of $24.99...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.